← FDA DRUG APPROVALS

FDA ANDA · ANDA062800

CLINDAMYCIN PHOSPHATE

Sponsor: ALMAJECT

APPLICATION
ANDA062800
TYPE
ANDA
ORIGINAL APPROVAL
1987-07-24
LATEST ACTION
2026-05-28
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CLINDAMYCIN PHOSPHATEDiscontinued
CLINDAMYCIN PHOSPHATE EQ 150MG BASE/ML · INJECTABLE · INJECTION

Approval history

2026-05-28Labeling · Supplement 41 · standardAP
2026-05-28Labeling · Supplement 38 · standardAP
2026-05-28Labeling · Supplement 36 · standardAP
2026-05-28Labeling · Supplement 40 · standardAP
2026-05-28Labeling · Supplement 39 · standardAP
2026-05-28Labeling · Supplement 35 · standardAP
2013-01-18Labeling · Supplement 31 · standardAP
2008-10-10Labeling · Supplement 25AP
2005-08-12Labeling · Supplement 20AP
2004-07-12Labeling · Supplement 15AP
2001-01-23Manufacturing (CMC) · Supplement 13AP
2000-10-26Labeling · Supplement 12AP
1998-08-03Manufacturing (CMC) · Supplement 11AP
1995-01-17Labeling · Supplement 10AP
1994-06-20Labeling · Supplement 9AP
1994-02-28Labeling · Supplement 7AP
1994-02-24Manufacturing (CMC) · Supplement 8AP
1991-10-22Labeling · Supplement 4AP
1987-07-24OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →